Suppr超能文献

靶向儿童癌症中的融合癌蛋白:开发治疗方法的挑战和未来机遇。

Targeting fusion oncoproteins in childhood cancers: challenges and future opportunities for developing therapeutics.

机构信息

Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

出版信息

J Natl Cancer Inst. 2024 Jul 1;116(7):1012-1018. doi: 10.1093/jnci/djae075.

Abstract

Fusion oncoproteins are associated with childhood cancers and have proven challenging to target, aside from those that include kinases. As part of its efforts for targeting childhood cancers, the National Cancer Institute recently conducted a series on Novel Chemical Approaches for Targeting Fusion Oncoproteins. Key learnings on leading platforms and technologies that can be used to advance the development of molecular therapeutics that target fusion oncoproteins in childhood cancers are described. Recent breakthroughs in medicinal chemistry and chemical biology provide new ground and creative strategies to exploit for the development of targeted agents for improving outcomes against these recalcitrant cancers.

摘要

融合致癌蛋白与儿童癌症有关,除了那些包含激酶的融合致癌蛋白外,其他的融合致癌蛋白靶向治疗一直极具挑战。作为其儿童癌症靶向治疗工作的一部分,美国国家癌症研究所最近开展了一系列关于“靶向融合致癌蛋白的新型化学方法”的研究。本文描述了可用于推进儿童癌症融合致癌蛋白的分子治疗开发的主要平台和技术。最近在药物化学和化学生物学方面的突破为开发针对这些难治性癌症的靶向药物提供了新的靶点和创新策略。

相似文献

2
TRK inhibitors in TRK fusion-positive cancers.
Ann Oncol. 2019 Nov;30 Suppl 8:viii23-viii30. doi: 10.1093/annonc/mdz282. Epub 2019 Dec 24.
3
Targeting cancer with kinase inhibitors.
J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.
4
Developmental origins and emerging therapeutic opportunities for childhood cancer.
Nat Med. 2019 Mar;25(3):367-376. doi: 10.1038/s41591-019-0383-9. Epub 2019 Mar 6.
5
Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy.
J Pediatr Pharmacol Ther. 2021;26(6):541-555. doi: 10.5863/1551-6776-26.6.541. Epub 2021 Aug 16.
6
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
Cell Rep. 2018 Apr 3;23(1):227-238.e3. doi: 10.1016/j.celrep.2018.03.050.
7
Emerging Targeted Therapy for Tumors with Fusion Proteins.
Clin Cancer Res. 2018 Dec 1;24(23):5807-5814. doi: 10.1158/1078-0432.CCR-18-1156. Epub 2018 Jul 9.
9
Targeting fusion proteins: a double edge sword?
Expert Opin Ther Targets. 2019 Aug;23(8):651-654. doi: 10.1080/14728222.2019.1628219. Epub 2019 Jun 6.

引用本文的文献

1
FusOn-pLM: a fusion oncoprotein-specific language model via adjusted rate masking.
Nat Commun. 2025 Feb 7;16(1):1436. doi: 10.1038/s41467-025-56745-6.

本文引用的文献

1
The rise of degrader drugs.
Cell Chem Biol. 2023 Aug 17;30(8):864-878. doi: 10.1016/j.chembiol.2023.06.020. Epub 2023 Jul 25.
2
Targeted protein degrader development for cancer: advances, challenges, and opportunities.
Trends Pharmacol Sci. 2023 May;44(5):303-317. doi: 10.1016/j.tips.2023.03.003.
3
Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions.
J Med Chem. 2023 Apr 27;66(8):5524-5535. doi: 10.1021/acs.jmedchem.2c01864. Epub 2023 Apr 10.
4
Autologous T cell therapy for MAGE-A4 solid cancers in HLA-A*02 patients: a phase 1 trial.
Nat Med. 2023 Jan;29(1):104-114. doi: 10.1038/s41591-022-02128-z. Epub 2023 Jan 9.
5
Machine Learning Modeling of Protein-intrinsic Features Predicts Tractability of Targeted Protein Degradation.
Genomics Proteomics Bioinformatics. 2022 Oct;20(5):882-898. doi: 10.1016/j.gpb.2022.11.008. Epub 2022 Dec 6.
6
Targeting RNA structures with small molecules.
Nat Rev Drug Discov. 2022 Oct;21(10):736-762. doi: 10.1038/s41573-022-00521-4. Epub 2022 Aug 8.
8
PROTAC targeted protein degraders: the past is prologue.
Nat Rev Drug Discov. 2022 Mar;21(3):181-200. doi: 10.1038/s41573-021-00371-6. Epub 2022 Jan 18.
9
A direct-to-biology high-throughput chemistry approach to reactive fragment screening.
Chem Sci. 2021 Aug 11;12(36):12098-12106. doi: 10.1039/d1sc03551g. eCollection 2021 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验